Gilman Hill Asset Management LLC Sells 3,160 Shares of GSK plc (NYSE:GSK)

Gilman Hill Asset Management LLC reduced its stake in shares of GSK plc (NYSE:GSK) by 4.7% in the 4th quarter, Holdings Channel reports. The firm owned 64,262 shares of the pharmaceutical company’s stock after selling 3,160 shares during the quarter. Gilman Hill Asset Management LLC’s holdings in GSK were worth $2,173,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. J2 Capital Management Inc bought a new stake in shares of GSK in the 4th quarter valued at $596,000. HF Advisory Group LLC grew its holdings in GSK by 12.8% during the 4th quarter. HF Advisory Group LLC now owns 8,743 shares of the pharmaceutical company’s stock worth $296,000 after acquiring an additional 990 shares during the period. Ameritas Advisory Services LLC raised its position in shares of GSK by 19.4% in the 4th quarter. Ameritas Advisory Services LLC now owns 34,955 shares of the pharmaceutical company’s stock worth $1,182,000 after acquiring an additional 5,668 shares in the last quarter. HB Wealth Management LLC acquired a new stake in shares of GSK during the 4th quarter worth approximately $316,000. Finally, Premier Path Wealth Partners LLC boosted its position in shares of GSK by 21.1% during the 4th quarter. Premier Path Wealth Partners LLC now owns 34,274 shares of the pharmaceutical company’s stock worth $1,159,000 after purchasing an additional 5,967 shares in the last quarter. Institutional investors and hedge funds own 15.74% of the company’s stock.

Analyst Ratings Changes

GSK has been the subject of a number of analyst reports. Guggenheim downgraded GSK from a “buy” rating to a “neutral” rating in a research note on Thursday, October 31st. StockNews.com raised shares of GSK from a “buy” rating to a “strong-buy” rating in a research report on Monday, January 13th. Jefferies Financial Group downgraded shares of GSK from a “buy” rating to a “hold” rating and reduced their price objective for the stock from $53.00 to $39.50 in a research report on Tuesday, November 12th. Finally, Deutsche Bank Aktiengesellschaft downgraded GSK from a “buy” rating to a “hold” rating in a research note on Friday, November 15th. Seven investment analysts have rated the stock with a hold rating and four have given a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $43.25.

GSK Stock Up 0.0 %

Shares of NYSE GSK opened at $33.46 on Monday. The stock has a market capitalization of $69.34 billion, a PE ratio of 21.72, a P/E/G ratio of 1.44 and a beta of 0.63. The company has a debt-to-equity ratio of 0.98, a current ratio of 0.81 and a quick ratio of 0.53. The business’s fifty day moving average price is $34.02 and its 200-day moving average price is $37.98. GSK plc has a one year low of $31.72 and a one year high of $45.92.

GSK Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, January 9th. Investors of record on Friday, November 15th were given a $0.3928 dividend. This represents a $1.57 dividend on an annualized basis and a dividend yield of 4.70%. The ex-dividend date of this dividend was Friday, November 15th. This is an increase from GSK’s previous quarterly dividend of $0.38. GSK’s dividend payout ratio (DPR) is 96.10%.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.